Concepedia

Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non–small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial

Martin Reck, Michael Schenker, Ki Hyeong Lee, Mariano Provencio, Makoto Nishio, Krzysztof Leśniewski-Kmak, Randeep Sangha, Samreen Ahmed, Judith Raimbourg, Kynan Feeney,

European Journal of Cancer · 2019 · 217 citations · 26 references

DOIFull text

Open access

Concepts

References

26

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

H. Borghaei, L. Paz-Ares, Leora Horn et al. · New England Journal of Medicine · 2015 · 9.5K citations · Full text

, , +17

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

Julie R. Brahmer, Karen L. Reckamp, Lucio Crinò et al. · New England Journal of Medicine · 2015 · 8.6K citations · Full text

, , +15

Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden

Matthew D. Hellmann, Tudor–Eliade Ciuleanu, Adam Płużański et al. · New England Journal of Medicine · 2018 · 3.1K citations · Full text

, , +17

Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance

Health and Quality of Life Outcomes · 2006 · 2.9K citations · Full text

, , +16

Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial

Ethan Basch, Allison M. Deal, Mark G. Kris et al. · Journal of Clinical Oncology · 2015 · 2.7K citations · Full text

, , +17